Gregor Kawaletz

Gregor Kawaletz graduated from the University of Cologne with a master’s degree in political science. He is a seasoned commercial leader with extensive 20 years of experience in the CDMO sector. With a robust track record of revenue growth, organisational transformation, and market positioning, he combines excellent CDMO industry insight, transactional experience, and people leadership to lead and create value in a CEO role. In recent years, he has been associated with companies NextPharma, Catalent, IDT-Biologika, Albumedix, Recipharm AB. Gregor Kawaletz is deeply experienced in industry trend analysis and go-to-market strategy, having successfully anticipated technology and therapeutic area trends, including oral biologics and ADCs (Antibody-Drug Conjugate). Throughout his career, he has consistently provided strategic direction grounded in market intelligence and operational feasibility. He has successfully anticipated the potential of ADCs as well as orally delivered biologics, leading internal alignment on a CAPEX plan and onboarding external partners, ultimately generating significant increase in revenue and profitability in Recipharm AB and other organisations he worked for. He has built relationships with multiple private equity and venture capital firms and has been trusted to lead sell-side and strategic transformations.